Numerate racks up $5.5M for drug engineering technology
Numerate, a San Bruno, Calif.-based biotech company that streamlines pharmaceutical production pipelines and intellectual property protections, brought in $5.5. million in a second round of funding, according to peHUB. Called the Drug Engineering Process, its system helps research teams set and methodically achieve milestones across different areas, the company says. In its two case studies, it refined therapies for diabetes and HIV.
The funds came from Foundation Capital and Lanza TechVentures. Numerate has bagged $4 million… Continue Reading
“Drug engineer” Numerate rises from the ashes of Pharmix
(UPDATED: See below.)
Numerate, a San Bruno, Calif., “drug engineer,” said it has acquired all intellectual-property assets of Pharmix, a Brisbane, Calif., startup that designed drugs via computer. The company’s release is here.
As you’d expect, Pharmix appears to be defunct; its Web site now defaults to that of Numerate, although I haven’t been able to find anything that points to its cause of death. (Third-degree cash burn seems as good a guess as any.) For a look… Continue Reading